세계의 증식성 당뇨막망병증(PDR) 시장 보고서(2025년)

Proliferative Diabetic Retinopathy (PDR) Global Market Report 2025

US $ 4,490 ￦ 6,371,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,209,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,048,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

증식성 당뇨망막병증(PDR) 시장 규모는 향후 몇 년 동안 빠르게 성장하여 2029년까지 10.5%의 연평균 복합 성장률(CAGR)로 40억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 인구 고령화, 당뇨병에 대한 대중의 인식과 교육, 연구 개발 자금, 병용요법에 대한 수요 증가에 기인하는 것으로 보입니다. 예측 기간 동안 주요 동향으로는 진단 기술의 발전, 치료 옵션의 혁신, 조기 진단을 위한 인공지능(AI), 유전자 치료의 발전, 첨단 망막 이미징 등이 있습니다.

당뇨병 유병률 증가는 증식성 당뇨망막병증(PDR) 시장의 성장을 가속할 것으로 예상됩니다. 당뇨병은 혈당 상승을 특징으로 하는 만성 질환으로 증식성 당뇨망막병증의 주요 원인이지만, 망막의 추가 손상을 방지하고 시력 유지에 도움이 되는 치료로 관리할 수 있습니다. 예를 들어, 2024년 6월 영국 국민보건서비스(NHS) 자료에 따르면 40세 미만 당뇨병 환자가 2022년 173,166명에서 2023년 216,440명으로 증가했습니다. 이러한 현저한 증가는 젊은 연령층에서 우려할 만한 추세를 강조하고 있습니다. 결과적으로, 당뇨병 유병률 증가는 PDR 시장을 발전시키는 중요한 요인이 되고 있습니다.

비만 유병률 증가는 증식성 당뇨망막병증(PDR) 시장의 향후 성장에 중요한 촉진요인이 될 것으로 예상됩니다. 비만은 다양한 요인을 가진 다면적 만성질환으로 체지방의 과잉 축적과 잠재적인 건강 문제를 초래합니다. 비만은 인슐린 저항성, 만성 저급 염증, 산화 스트레스 증가와 밀접한 관련이 있으며, 이 모든 것이 망막 미세혈관계에 악영향을 미쳐 당뇨망막병증 발병의 원인이 될 수 있습니다. 예를 들어, 미국 비영리 단체인 Trust for America's Health가 2022년에 발표한 보고서에 따르면 미국의 비만율은 상승 추세에 있으며, 미국 성인 10명 중 4명이 비만의 영향을 받고 있습니다. 이는 전년 대비 증가한 것으로, 성인 비만율이 35% 이상이라고 보고한 주(州)는 19개 주(州)로, 전년도 16개 주에서 증가한 것으로 나타났습니다. 그 결과, 비만 증가는 증식성 당뇨망막병증(PDR) 시장 확대를 촉진하는 매우 중요한 촉매제가 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 증식성 당뇨막망병증(PDR) PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
• 최종 이용 산업 분석
• 세계의 증식성 당뇨막망병증(PDR) 시장 : 성장률 분석
• 세계의 증식성 당뇨막망병증(PDR) 시장 실적 : 규모와 성장, 2019-2024
• 세계의 증식성 당뇨막망병증(PDR) 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 증식성 당뇨막망병증(PDR) 전체 시장(TAM)

제6장 시장 세분화

• 세계의 증식성 당뇨막망병증(PDR) 시장 : 치료 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 항VEGF(혈관내피세포성장인자) 요법
• 안내 스테로이드
• 레이저 수술
• 유리체 절제술
• 세계의 증식성 당뇨막망병증(PDR) 시장 : 투여 방법별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 주사제
• 경구
• 기타 관리 방법
• 세계의 증식성 당뇨막망병증(PDR) 시장 : 용도별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 클리닉
• 기타 용도
• 세계의 증식성 당뇨막망병증(PDR) 시장 : 항VEGF 요법 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Aflibercept
• Ranibizumab
• Bevacizumab
• 세계의 증식성 당뇨막망병증(PDR) 시장 : 안내 스테로이드별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Triamcinolone Acetonide
• Dexamethasone Implant
• Fluocinolone Acetonide
• 세계의 증식성 당뇨막망병증(PDR) 시장 : 레이저 수술 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 국소 레이저 광응고술
• 망막 레이저 광응고술
• 세계의 증식성 당뇨막망병증(PDR) 시장 유리체 절제술별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 유리체 절제술
• 전방 유리체 절제술

제7장 지역별/국가별 분석

• 세계의 증식성 당뇨막망병증(PDR) 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 증식성 당뇨막망병증(PDR) 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 증식성 당뇨막망병증(PDR) 시장 : 경쟁 구도
• 증식성 당뇨막망병증(PDR) 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• Bayer AG
• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• GSK plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Novo Nordisk A/S
• Boehringer Ingelheim International GmbH
• Merck KGaA
• Kubota Vision Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 증식성 당뇨막망병증(PDR) 시장(2029년) : 새로운 기회를 제공하는 국가
• 증식성 당뇨막망병증(PDR) 시장(2029년) : 새로운 기회를 제공하는 부문
• 증식성 당뇨막망병증(PDR) 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Proliferative diabetic retinopathy (PDR) represents an advanced stage of diabetic eye disease marked by the development of abnormal blood vessels in the retina. This occurrence is primarily attributed to prolonged high levels of blood sugar. If left unaddressed, these abnormal vessels can result in retinal bleeding, scarring, and impaired vision. Consequently, regular eye examinations are of paramount importance for early detection and effective management.

The primary treatment options for proliferative diabetic retinopathy encompass anti-VEGF (vascular endothelial growth factor) therapy, intraocular steroids, laser surgery, and vitrectomy. Intraocular steroids involve the direct administration of medications into the eye, which serves to address inflammation and manage conditions like diabetic macular edema or uveitis. This approach aids in reducing swelling and enhancing visual outcomes. Various modes of administration, including injectables, oral medications, and others, find application in settings such as hospitals, clinics, and more.

The proliferative diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides proliferative diabetic retinopathy market statistics, including proliferative diabetic retinopathy industry global market size, regional shares, competitors with a proliferative diabetic retinopathy market share, detailed proliferative diabetic retinopathy market segments, market trends and opportunities and any further data you may need to thrive in the proliferative diabetic retinopathy industry. This proliferative diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The proliferative diabetic retinopathy (PDR) market size has grown rapidly in recent years. It will grow from $2.42 billion in 2024 to $2.7 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to growing diabetes prevalence, changes in lifestyle and intake of unhealthy foods, government initiatives, rising numbers of diabetes-related loss of vision.

The proliferative diabetic retinopathy (PDR) market size is expected to see rapid growth in the next few years. It will grow to $4.02 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to aging population, public awareness and education about diabetes, research and development funding, rising demand for combination therapies. Major trends in the forecast period include advancements in diagnostic technologies, innovations in treatment options, artificial intelligence (AI) for early diagnosis, gene therapy advancements, advanced retinal imaging.

The increasing prevalence of diabetes is anticipated to drive growth in the proliferative diabetic retinopathy (PDR) market. Diabetes, a chronic condition marked by elevated blood glucose levels, is the primary cause of proliferative diabetic retinopathy, which can be managed with treatments that prevent further retinal damage and help preserve vision. For example, in June 2024, data from the UK's National Health Service (NHS) showed a rise in diabetes cases among individuals under 40, from 173,166 in 2022 to 216,440 in 2023. This notable increase underscores a concerning trend in younger populations. Consequently, the rising diabetes prevalence is a key factor driving the PDR market forward.

The increasing prevalence of obesity is expected to be a key driver for the future growth of the proliferative diabetic retinopathy (PDR) market. Obesity, a multifaceted, chronic condition with various contributing factors, results in an excess accumulation of body fat and potential health issues. Obesity is closely associated with insulin resistance, chronic low-grade inflammation, and heightened oxidative stress, all of which can adversely affect the retinal microvasculature and contribute to the onset of diabetic retinopathy. For instance, according to a 2022 report released by Trust for America's Health, a non-profit organization in the United States, obesity rates in the country are on the rise, with four out of every ten American adults being affected by obesity. This represents an increase compared to the previous year, with 19 states reporting adult obesity rates exceeding 35%, up from 16 states in the preceding year. Consequently, the escalating prevalence of obesity serves as a pivotal catalyst driving the expansion of the proliferative diabetic retinopathy (PDR) market.

Prominent companies operating in the proliferative diabetic retinopathy market maintain a consistent focus on the development of groundbreaking therapies. This strategic emphasis aims to enhance treatment efficacy, alleviate the treatment-related financial burden, and ultimately elevate patient outcomes. For instance, in June 2022, Biogen, a leading US-based biotechnology company, partnered with Samsung Bioepis, a South Korea-based biotech company, to introduce Byooviz (ranibizumab-nuna). Byooviz represents the first ophthalmology biosimilar in the United States, offering treatment options for patients dealing with diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization. These innovative therapies are poised to bring transformative changes to the landscape of proliferative diabetic retinopathy treatment.

In July 2024, Merck & Co., Inc., a U.S.-based healthcare company specializing in medicines, vaccines, and animal health products, acquired Eyebiotech Limited for $3 billion. Through this acquisition, Merck aims to strengthen its ophthalmology pipeline by advancing innovative treatments for sight-threatening retinal diseases and addressing critical unmet needs in this field. Eyebiotech Limited, a UK-based biotechnology company, focuses on developing therapies for proliferative diabetic retinopathy to counteract abnormal retinal blood vessel growth.

Major companies operating in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the proliferative diabetic retinopathy (PDR) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The proliferative diabetic retinopathy (PDR) market consists of sales of laser therapy, systemic therapies and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The proliferative diabetic retinopathy (PDR) market also includes sales of corticosteroids, ranibizumab, bevacizumab and fluocinolone acetonide drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Proliferative Diabetic Retinopathy (PDR) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on proliferative diabetic retinopathy (pdr) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for proliferative diabetic retinopathy (pdr) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The proliferative diabetic retinopathy (pdr) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy; Intraocular Steroids; Laser Surgery; Vitrectomy
• 2) By Mode of Administration: Injectables; Oral; Other Mode Of Administrations
• 3) By Application: Hospitals; Clinics; Other Applications
• Subsegments:
• 1) By Anti-VEGF Therapy: Aflibercept; Ranibizumab; Bevacizumab
• 2) By Intraocular Steroids: Triamcinolone Acetonide; Dexamethasone Implant; Fluocinolone Acetonide
• 3) By Laser Surgery: Focal Laser Photocoagulation; Panretinal Laser Photocoagulation
• 4) By Vitrectomy: Pars Plana Vitrectomy; Anterior Vitrectomy
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; F. Hoffmann-La Roche Ltd.; Merck and Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Proliferative Diabetic Retinopathy (PDR) Market Characteristics

3. Proliferative Diabetic Retinopathy (PDR) Market Trends And Strategies

4. Proliferative Diabetic Retinopathy (PDR) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Proliferative Diabetic Retinopathy (PDR) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Proliferative Diabetic Retinopathy (PDR) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Proliferative Diabetic Retinopathy (PDR) Market Growth Rate Analysis
• 5.4. Global Proliferative Diabetic Retinopathy (PDR) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Proliferative Diabetic Retinopathy (PDR) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Proliferative Diabetic Retinopathy (PDR) Total Addressable Market (TAM)

6. Proliferative Diabetic Retinopathy (PDR) Market Segmentation

• 6.1. Global Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-VEGF (Vascular Endothelial Growth Factor) Therapy
• Intraocular Steroids
• Laser Surgery
• Vitrectomy
• 6.2. Global Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectables
• Oral
• Other Mode Of Administrations
• 6.3. Global Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other Applications
• 6.4. Global Proliferative Diabetic Retinopathy (PDR) Market, Sub-Segmentation Of Anti-VEGF Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aflibercept
• Ranibizumab
• Bevacizumab
• 6.5. Global Proliferative Diabetic Retinopathy (PDR) Market, Sub-Segmentation Of Intraocular Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Triamcinolone Acetonide
• Dexamethasone Implant
• Fluocinolone Acetonide
• 6.6. Global Proliferative Diabetic Retinopathy (PDR) Market, Sub-Segmentation Of Laser Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Focal Laser Photocoagulation
• Panretinal Laser Photocoagulation
• 6.7. Global Proliferative Diabetic Retinopathy (PDR) Market, Sub-Segmentation Of Vitrectomy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pars Plana Vitrectomy
• Anterior Vitrectomy

7. Proliferative Diabetic Retinopathy (PDR) Market Regional And Country Analysis

• 7.1. Global Proliferative Diabetic Retinopathy (PDR) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Proliferative Diabetic Retinopathy (PDR) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market

• 8.1. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Proliferative Diabetic Retinopathy (PDR) Market

• 9.1. China Proliferative Diabetic Retinopathy (PDR) Market Overview
• 9.2. China Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Proliferative Diabetic Retinopathy (PDR) Market

• 10.1. India Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Proliferative Diabetic Retinopathy (PDR) Market

• 11.1. Japan Proliferative Diabetic Retinopathy (PDR) Market Overview
• 11.2. Japan Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Proliferative Diabetic Retinopathy (PDR) Market

• 12.1. Australia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Proliferative Diabetic Retinopathy (PDR) Market

• 13.1. Indonesia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Proliferative Diabetic Retinopathy (PDR) Market

• 14.1. South Korea Proliferative Diabetic Retinopathy (PDR) Market Overview
• 14.2. South Korea Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Proliferative Diabetic Retinopathy (PDR) Market

• 15.1. Western Europe Proliferative Diabetic Retinopathy (PDR) Market Overview
• 15.2. Western Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Proliferative Diabetic Retinopathy (PDR) Market

• 16.1. UK Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Proliferative Diabetic Retinopathy (PDR) Market

• 17.1. Germany Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Proliferative Diabetic Retinopathy (PDR) Market

• 18.1. France Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Proliferative Diabetic Retinopathy (PDR) Market

• 19.1. Italy Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Proliferative Diabetic Retinopathy (PDR) Market

• 20.1. Spain Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market

• 21.1. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market Overview
• 21.2. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Proliferative Diabetic Retinopathy (PDR) Market

• 22.1. Russia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Proliferative Diabetic Retinopathy (PDR) Market

• 23.1. North America Proliferative Diabetic Retinopathy (PDR) Market Overview
• 23.2. North America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Proliferative Diabetic Retinopathy (PDR) Market

• 24.1. USA Proliferative Diabetic Retinopathy (PDR) Market Overview
• 24.2. USA Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Proliferative Diabetic Retinopathy (PDR) Market

• 25.1. Canada Proliferative Diabetic Retinopathy (PDR) Market Overview
• 25.2. Canada Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Proliferative Diabetic Retinopathy (PDR) Market

• 26.1. South America Proliferative Diabetic Retinopathy (PDR) Market Overview
• 26.2. South America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Proliferative Diabetic Retinopathy (PDR) Market

• 27.1. Brazil Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Proliferative Diabetic Retinopathy (PDR) Market

• 28.1. Middle East Proliferative Diabetic Retinopathy (PDR) Market Overview
• 28.2. Middle East Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Proliferative Diabetic Retinopathy (PDR) Market

• 29.1. Africa Proliferative Diabetic Retinopathy (PDR) Market Overview
• 29.2. Africa Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Proliferative Diabetic Retinopathy (PDR) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Proliferative Diabetic Retinopathy (PDR) Market Competitive Landscape And Company Profiles

• 30.1. Proliferative Diabetic Retinopathy (PDR) Market Competitive Landscape
• 30.2. Proliferative Diabetic Retinopathy (PDR) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Proliferative Diabetic Retinopathy (PDR) Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. Sanofi S.A.
• 31.4. Bristol-Myers Squibb Company
• 31.5. AstraZeneca plc
• 31.6. GSK plc
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Eli Lilly and Company
• 31.9. Amgen Inc.
• 31.10. Novo Nordisk A/S
• 31.11. Boehringer Ingelheim International GmbH
• 31.12. Merck KGaA
• 31.13. Kubota Vision Inc.
• 31.14. Teva Pharmaceutical Industries Ltd.
• 31.15. Regeneron Pharmaceuticals Inc.

32. Global Proliferative Diabetic Retinopathy (PDR) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Proliferative Diabetic Retinopathy (PDR) Market

34. Recent Developments In The Proliferative Diabetic Retinopathy (PDR) Market

35. Proliferative Diabetic Retinopathy (PDR) Market High Potential Countries, Segments and Strategies

• 35.1 Proliferative Diabetic Retinopathy (PDR) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Proliferative Diabetic Retinopathy (PDR) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Proliferative Diabetic Retinopathy (PDR) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료